Mainland Chinese investors can now buy shares in more than a dozen newly added Hong Kong-listed biotech and pharmaceutical companies after a reshuffle of the Stock Connect southbound trading list took effect on Monday, reflecting the sector’s growing role on the international stage.
Foreign capital, however, remained cautious, analysts said.
“Mainland buyers have been the main force behind the latest healthcare rally. They tend to chase smaller-cap names where a tight free float makes it easier…
